Business
Vor to Present New Data on its Cell and Genome Engineering Platform at SITC Annual Meeting
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the
About this update from Vor Biopharma Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the presentation of new data from its novel cell therapy platform at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, taking place in Washington D.C., from November 10-14, 2021. The preclinical research supports a novel therapeutic approach to a subtype of acute myeloid leukemia (AML) using a cytokine tethered to the surface of a T cell (a “zetakine”) designed to enhance tumor cell killing without inducing acute T cell hyperactivation. Vor also demonstrated its optimization of a high-throughput, fluorescent-protein based platform used for the screening of different chimeric antigen receptor (CAR) constructs and their potential to induce efficient T cell activation. “Vor is rapidly advancing multiple areas of innovation in cell and genome engineering to unlock the full potential of this field for blood cancer patients,” said Tirtha Chakraborty, Ph.D., Vor’s Chief Scientific Officer. “This supportive initial data of a novel zetakine approach to target CD123 expressing leukemic cells provides a foundation for broader work to develop potentially differentiated therapies for patients with acute myeloid leukemia. We are also thrilled to present data related to our optimization of a high-throughput, fluorescent-protein based screening platform used to assess different CAR constructs for efficient T cell activation, which may accelerate the development of research candidates.” SITC Annual Meeting Presentations Poster PresentationTitle: Construction and Evaluation of Interleukin 3 (IL3)-Zetakine Redirected Cytolytic T Cells for the Treatment of CD123 Expressing Acute Myeloid LeukemiaAbstract ID Number: 15797Poster Presentation: 871Presenting Author: Rebecca Moeller, MSc, Associate Scientist II, Cancer Immunotherapy, Vor Date: Friday, November 12, 2021, through Saturday, November 13, 2021 Time: 7:00am ET - 8:30pm ET Poster PresentationTitle: An NFAT Promoter Based Fluorescent Jurkat Cell Platform for High-Throughput Screening of Chimeric Antigen Receptor (CAR) ConstructsAbstract ID Number: 16305Poster Presentation: 115Presenting Author: Brikena Gjeci, MS, Associate Scientist II, Cancer Immunotherapy, Vor Date: Friday, November 12, 2021, through Saturday, November 13, 2021...